"Alkoclar and his previous R&D team; Halepce R&D has found and patented more than 154 methylprotodioscin derivatives; analogues used in a wide range of therapeutic fields such as neurogenesis to myogenesis; from height increase (despite the inconsistent results obtained from the formulation regarding the oral version) to adjuvant cancer therapies. Alkoclar is the sole inventor of the facile obtaining methods of hexacoumaroyl-protobioside derivatives; compounds which possesses potent Core GLC NAC III inhibiting properties."
This is probably a fragment of his statement.
"They did with varying consistencies, We were unable to eliminate or at least sufficientşy reduce the side effects associated with thhe chronic use of related compounds. Latest and the most promising formula consists 3 iridoid glycoside derivatives and a furostanol saponin analouge and the mechanism was tissue selective enhancement of KSBGF, a bone growth factor with potent tgf-b expression enhancement properties. We were trying to obtain semi synthetic compounds with a purpose oriented modification process; we were trying to degrade a 50 purpose natural ingredient to a one purpose small molecular combination but this was never the answer.
After a year of consistent effort we were finally able to obtain an efficient formulation with a stable and facile method of synthesis. A small pre clinical trial involving 7 people had been done and an avarage height gain of 1.9 cm was observed in 5 months of intentional irregular usage in order to avoid possible side effects. Out of 7 users all of them experienced increased aggression due to elevated cGmp and reduced cAmp in Amygdala and hypothalmic regions.
4 out of 7 experienced severe carpal tunnel like symptoms with a significant loss of limb function. Same partipicants also suffered from prostate inflammation and elevated Psa levels.
1 participant experienced nocturnal breathlessness.All participants have grown. Despite the success in terms of vertical bone growth side effects hindered projects’ advancement"
